Detecting leukemia stem cells in blood and bone marrow to predict relapse in acute leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to improve the prediction of relapse in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) by using multiparametric flow cytometry to detect circulating leukemia stem cells. The study focuses on newly diagnosed patients under 18 years old who can provide informed consent. By identifying these stem cells, the researchers hope to enhance the accuracy of relapse predictions and potentially guide preemptive therapies. The study is being conducted at multiple centers, including Peking University People's Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Newly diagnoses candidates with acute myeloid leukemia.
* Lower than or equal to 18 years-old;
* Subjects are able to provide written informed consent.

Exclusion Criteria:

* Subjects who cannot comply with the study;
* Subjects with severe cardiac disease (ejection fraction\<50% ), liver disease (total bilirubin \>34umol/L, ALT and AST\>1.5×upper limit normal) or kidney disease (Serum creatinine\>130umol/L).
* Subjects with severe infection.
* Subjects with other conditions that cannot receive chemotherapy or transplantation.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting
• People's Hospital of Peking University
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Yingjun Chang Y Prof. Ying-Jun Chang Chang
• Email: rmcyj@bjmu.edu.cn
• Phone: 8610-88325949

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• FXS0683 in relapsed or refractory blood cancers

  This first‑in‑human study tests FXS0683 in adults with relapsed or refractory B‑cell lymphoma, AML, MDS, or ALL to see if it is safe, how the drug behaves in the body, and whether it shows any antitumor activity.

  Recruiting Phase 1 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Tianjin, Tianjin Municipality · NCT07616089

• CD19-targeted CAR-T cells that make p40 for relapsed or refractory CD19-positive blood cancers

  This trial will try a patient's own CD19-directed CAR-T cells engineered to produce p40 to see if they work better and last longer in adults with relapsed or refractory CD19-positive blood cancers.

  Recruiting Phase 1/2 Shenzhen University General Hospital · Shenzhen, Other (Non U.s.) · NCT07584889

• Revumenib with Mezigdomide for relapsed or refractory acute leukemia

  This trial will test whether combining revumenib and mezigdomide is safe for people aged 12 and older with relapsed or refractory acute leukemia that has KMT2A, NUP98, or NPM1 genetic changes.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Duarte, California and 9 other locations · NCT07356154

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Efficacy and safety of TmBU conditioning for high-risk leukemia patients

  This study is testing a new treatment approach for high-risk leukemia patients to see if it helps them stay cancer-free after a stem cell transplant better than the current method.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06816134

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.